Physician profile
Joseph Pitcher
NPI 1962721902
$3,839.90
in general payments reported to CMS, 2019-2025
17 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 82% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $312 · 2021: $53.64 · 2022: $560 · 2023: $483 · 2024: $924 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,055.80 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Inari Medical, INC. | $637.26 | 2020-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Glaxosmithkline, LLC. | $459.69 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $350.77 | 2021-2025 | |
| Verona Pharma, INC. | $321.94 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $198.04 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.58 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $174.68 | 2022-2024 | Yupelri |
| Pulmonx Corporation | $141.87 | 2019-2022 | |
| Stryker Corporation | $91.74 | 2025 | Flowtriever |
| Takeda Pharmaceuticals U.S.A., INC. | $82.14 | 2024-2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $35.41 | 2024 | Acthar |
| Grifols USA, LLC | $30.89 | 2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $24.04 | 2024 | Opsumit |
| Viatris Specialty LLC | $18.53 | 2025 | Yupelri |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $15.68 | 2025 | Arikayce |
| Teva Pharmaceuticals USA, INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pitcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.